×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
LON:IXI

IXICO (IXI) Share Forecast, Price & News

GBX 38
0.00 (0.00%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
37.06
39.92
50-Day Range
33.45
42
52-Week Range
32.50
94.20
Volume
11,141 shs
Average Volume
38,635 shs
Market Capitalization
£18.30 million
P/E Ratio
20.00
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IXI News and Ratings via Email

Sign-up to receive the latest news and ratings for IXICO and its competitors with MarketBeat's FREE daily newsletter.

IXICO logo

About IXICO

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
93
Year Founded
N/A

Sales & Book Value

Annual Sales
£8.20 million
Cash Flow
GBX 12 per share
Book Value
GBX 24 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£18.30 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/20/2020
Today
5/27/2022

MarketRank

Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













IXICO (LON:IXI) Frequently Asked Questions

Is IXICO a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IXICO in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IXICO stock.
View analyst ratings for IXICO
or view top-rated stocks.

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) announced its quarterly earnings results on Wednesday, May, 20th. The company reported $1.01 EPS for the quarter.
View IXICO's earnings history
.

Who are IXICO's key executives?
IXICO's management team includes the following people:
  • Mr. Giulio Cerroni, CEO & Director (Age 60, Pay $415.28k)
  • Mr. Grant Nash, CFO, Company Sec. & Exec. Director
  • Prof. Daniel Rueckert, Co-Founder & Member of Scientific Advisory Board
  • Prof. Derek Lionel Glendon Hill, Co-Founder and Pres of Regulatory Science & External Relations (Age 56)
  • Prof. David Hawkes, Co-Founder & Member of Scientific Advisory Board
  • Prof. Joseph Hajnal, Co-Founder & Member of Scientific Advisory Board
  • Mr. Marcus Thornton, Chief Operating Officer
  • Mr. Mark Austin, Director of Technology
  • Dr. Robin Wolz, Chief Scientific Officer
  • Ms. Hannah Esfahanian, HR Mang.
What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IXICO investors own include Motif Bio (MTFB), ReNeuron Group (RENE), Pendragon (PDG), EnQuest (ENQ) and Chariot (CHAR).

What is IXICO's stock symbol?

IXICO trades on the London Stock Exchange (LON) under the ticker symbol "IXI."

How do I buy shares of IXICO?

Shares of IXI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is IXICO's stock price today?

One share of IXI stock can currently be purchased for approximately GBX 38.

How much money does IXICO make?

IXICO has a market capitalization of £18.30 million and generates £8.20 million in revenue each year.

How many employees does IXICO have?

IXICO employs 93 workers across the globe.

What is IXICO's official website?

The official website for IXICO is ixico.com.

How can I contact IXICO?

IXICO's mailing address is 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN, United Kingdom. The company can be reached via phone at +44-20-37637499.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.